Disease · MONDO_0013600

insomnia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. insomnia. Diseases, record MONDO_0013600. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0013600

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: insomnia; Open Targets
Open Targets ID: MONDO_0013600; Open Targets
Other names: insomnia (disease); Open Targets
MeSH: D007319; MeSH
NCI Thesaurus: C28286; NCI Thesaurus
Highest stage of its drugs: Approval, for 41 of its 118 drugs, from DailyMed, FDA, PMDA and TTD; Open Targets

Drugs118

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ZOLPIDEM	CHEMBL911	Small molecule	Approval	TTD	39	38	38	Drugs and targets
RAMELTEON	CHEMBL1218	Small molecule	Approval	DailyMed, PMDA and TTD	39	32	32	Drugs and targets
ESZOPICLONE	CHEMBL1522	Small molecule	Approval	DailyMed, PMDA and TTD	67	26	26	Drugs and targets
SUVOREXANT	CHEMBL1083659	Small molecule	Approval	DailyMed, PMDA and TTD	24	21	21	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Approval	TTD	21	20	20	Drugs and targets
LEMBOREXANT	CHEMBL3545367	Small molecule	Approval	DailyMed, FDA, PMDA and TTD	22	18	18	Drugs and targets
GABOXADOL	CHEMBL312443	Small molecule	Approval	TTD	16	15	14	Drugs and targets
DARIDOREXANT	CHEMBL4297590	Small molecule	Approval	TTD	13	11	11	Drugs and targets
ZOPICLONE	CHEMBL135400	Small molecule	Approval	TTD	10	9	9	Drugs and targets
ZOLPIDEM TARTRATE	CHEMBL3989820	Small molecule	Approval	DailyMed	128	6	6	Drugs and targets

1 to 10 of 118

See all 118 drugs

Targets79

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA A receptor alpha-1/beta-1/gamma-2	25	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA receptor alpha-1 subunit positive allosteric modulator; GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2554	Drugs and targets
GABRB1	GABA A receptor alpha-1/beta-1/gamma-2	24	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2560	Drugs and targets
GABRG2	GABA A receptor alpha-1/beta-1/gamma-2	23	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2566	Drugs and targets
GABRA4	GABA-A receptor; agonist GABA site	22	GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator; Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta agonist	Approval	https://conductscience.org/library/genes/2557	Drugs and targets
GABRB3	GABA-A receptor; agonist GABA site	22	GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator; Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta agonist	Approval	https://conductscience.org/library/genes/2562	Drugs and targets
GABRA2	GABA-A receptor; agonist GABA site	21	GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; agonist GABA site	21	GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA5	GABA-A receptor; agonist GABA site	21	GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; agonist GABA site	21	GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB2	GABA-A receptor; agonist GABA site	21	GABA-A receptor; agonist GABA site positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel partial agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2561	Drugs and targets

1 to 10 of 79

See all 79 targets

Trials287

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02058992	Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty		3,339	2016-07-14	Insomnia	RAMELTEON	Its record names the disease	ClinicalTrials.gov
NCT01097616	Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)	Phase 3	1,023	2014-09-01	Primary Insomnia	SUVOREXANT	Its record names the disease	ClinicalTrials.gov
NCT01097629	Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)	Phase 3	1,020	2014-09-01	Primary Insomnia	SUVOREXANT	Its record names the disease	ClinicalTrials.gov
NCT02952820	Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)	Phase 3	971	2020-01-21	Insomnia Disorder	LEMBOREXANT	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00397189	Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients	Phase 3	930	2011-03-28	Primary Insomnia	MELATONIN	Its record names the disease	ClinicalTrials.gov
NCT03545191	Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder	Phase 3	930	2022-03-25	Insomnia Disorder	DARIDOREXANT	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03575104	Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep	Phase 3	924	2022-03-25	Insomnia Disorder	DARIDOREXANT	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03679884	Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep	Phase 3	804	2022-03-02	Insomnia Disorder	DARIDOREXANT	Its record names the disease	ClinicalTrials.gov
NCT01021813	A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)	Phase 3	781	2014-08-29	Insomnia	SUVOREXANT	Its record names the disease	ClinicalTrials.gov
NCT00608985	Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia	Phase 3	709	2013-02-07	Primary Insomnia	ALMOREXANT, ZOLPIDEM	Its record names the disease	ClinicalTrials.gov

1 to 10 of 287

See all 287 trials

Comparisons in its trials65

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Circadin vs Placebo: serious adverse events	1 of 394	3 of 395	789	NCT00397189	Trial comparisons
Suvorexant vs Placebo: Number of Participants Who Reported Suicidal Ideation and/or Behavior On Study Based on Responses to the Columbia Suicide Severity Rating Scale (C-SSRS)	6 of 521	0 of 258	779	NCT01021813	Trial comparisons
Esmirtazapine 4.5 mg vs Placebo: Number of Participants Who Experienced Adverse Events (AEs)	253 of 342	75 of 115	457	NCT00631657	Trial comparisons
Esmirtazapine 4.5 mg vs Placebo: Number of Participants Who Discontinued Study Drug Due to an AE	47 of 342	7 of 115	457	NCT00631657	Trial comparisons
Esmirtazapine 4.5 mg vs Placebo: serious adverse events	8 of 342	2 of 115	457	NCT00631657	Trial comparisons
Tasimelteon vs Placebo: deaths from any cause	0 of 160	0 of 160	320	NCT03373201	Trial comparisons
Tasimelteon vs Placebo: serious adverse events	1 of 160	0 of 160	320	NCT03373201	Trial comparisons
Zolpidem 3.5 mg vs Placebo: serious adverse events	0 of 150	0 of 145	295	NCT00466193	Trial comparisons
Suvorexant vs Placebo: deaths from any cause	0 of 142	0 of 143	285	NCT02750306	Trial comparisons
Suvorexant vs Placebo: serious adverse events	1 of 142	0 of 143	285	NCT02750306	Trial comparisons

1 to 10 of 65

See all 65 comparisons in its trials

Papers from its trials182

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38186562	RESULT	1	PubMed
36806948	RESULT	1	PubMed
35112665	RESULT	1	PubMed
35065036	RESULT	2	PubMed
34400769	RESULT	1	PubMed
33414503	RESULT	1	PubMed
32208051	RESULT	1	PubMed
31480717	RESULT	1	PubMed
31178410	RESULT	1	PubMed
31006331	RESULT	1	PubMed

1 to 10 of 182

See all 182 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0013600

GET https://conductscience.org/api/diseases/v1/MONDO_0013600/drugs?page=2

API reference For AI assistants